Scientists Find Biological Signals To Predict Course Of Chronic Kidney Disease
The team from The University of Manchester showed that higher levels of Kidney Injury Molecule-1(KIM-1) -- a special marker of kidney damage in the blood and urine -- are associated with higher risks of mortality and kidney failure.
Last month, the team measured 21 markers in blood and urine that reflect key processes driving kidney disease, inflammation, and heart disease.
Unlike the generic tests used in routine kidney clinics, these markers shine a light on the biological changes, underpinning CKD, that truly drive the disease.
By revealing the hidden drivers, the discovery opens the door to new treatments designed to target the disease at its roots.
“The progression of chronic kidney disease is highly variable between people, so it's difficult to predict which patients will progress to kidney failure or worse,” said lead author Dr Thomas McDonnell, from the varsity.
“But our work raises the prospect of the development of simple blood or urine tests that could better predict the degree of risk -- invaluable information for doctors and patients.
“We think that these models, which are more closely aligned with the underlying biological changes happening in chronic kidney disease, could allow a more tailored approach to the individual needs of patients,” McDonnell said.
In the study, published in the American Journal of Nephrology, the researchers analysed the blood and urine of adults with non-dialysis chronic kidney disease from 16 nephrology centres across the UK.
They analysed blood and urine KIM-1 in 2581 patients for the KIM-1 study. Separately, they looked at 21 markers of kidney damage (identified by the researchers in a study last month), fibrosis, inflammation, and cardiovascular disease in a second set of 2,884 patients.
Using statistical analysis, the team could assess how or if biological signals associated with kidney failure and mortality, and developed risk prediction models.
“This discovery may help doctors identify high-risk patients, so they enact more aggressive interventions, earlier specialist referral, and earlier treatment therapies,” McDonnell said, adding that“by identifying low-risk patients, they would be able to prevent over-treatment".

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Stonehaven Circle Marks 13Th Anniversary With Hadrian Colwyn Leading Calvio Ailegacyx Innovation
- Bitmex Launches Alpha Showdown Trading Competition Featuring 3 BTC Prize Pool And Additional Rewards
- Thrivestate Launches“Fly Before You Buy” Program, Enabling International Buyers To Explore Dubai Before Committing
- 1Inch Becomes First Swap Provider Relaunched On OKX Wallet
- Ozak AI Partners With Pyth Network To Deliver Real-Time Market Data Across 100+ Blockchains
- Xfunded Expands In Dubai, Strengthening Collaborations With Trading Influencers Across Europe
Comments
No comment